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ABSTRACT
Immunostimulatory CpG oligodeoxynucleotides (ODNs) can enhance
the therapeutic effect of monoclonal antibodies (mAbs) by enhancing
antibody-dependent cell-mediated cytotoxicity (ADCC). Distinct classes of
CpG ODNs have been found recently to stimulate different effector cell
populations. We used murine cancer models to explore the role of various
effector cell populations in the antitumor activity seen with mAbs com-
bined with CpG ODNs of the A and B classes. In the 38C13 syngeneic
murine lymphoma model, both CpG A and CpG B enhanced the efficacy
of murine antilymphoma mAb. Depletion of natural killer (NK) cells alone
markedly decreased the efficacy of therapy with mAbs plus CpG A. In
contrast, depletion of both NK cells and granulocytes was required to
decrease the efficacy of mAb plus CpG B. A human (h) Fc  receptor I
(FcRI)-expressing transgenic (Tg) mouse model was used to explore the
role of FcRI in therapy with mAb and CpG ODN. CpG B induced
up-regulation of FcRI in hFcRI Tg mice, whereas CpG A did not. In
vitro CpG B also enhanced ADCC of HER-2/neu-expressing tumor cells by
the FcRI-directed bispecific antibody MDX-H210 using hFcRI-positive
effector cells. In a solid tumor model, tumor growth was inhibited in Tg
mice treated with a combination of MDX-H210 and CpG B. These data
suggest that CpG A enhance ADCC largely by activating NK cells. In
contrast, other effector cell populations, including granulocytes, contrib-
ute to the antitumor activity of CpG B and mAbs. FcRI plays an
important role in this activity.
INTRODUCTION
mAbs3 have been a valuable addition to current cancer treatment
modalities. Recent experience with mAbs such as rituximab and
trastuzumab demonstrate that these drugs are well-tolerated and ca-
pable of initiating tumor regression in a significant percentage of
patients (1, 2). Unfortunately, the majority of patients treated with
mAbs exhibit only short-lived partial responses. Our current under-
standing of the mode of action of therapeutic mAbs is incomplete (3).
A variety of mechanisms may be important including blocking of
activation signals, induction of growth arrest, induction of apoptosis,
complement mediated lysis, and ADCC (4–6). A greater understand-
ing of the mechanisms underlying mAb-induced antitumor activity is
essential if we are to develop rationally designed immunotherapeutic
protocols that improve on current clinical results. Ab dependent
cell-mediated cytotoxicity mediated by FcRs appears to be critical for
many mAb-induced antitumor effects (7, 8). Immunotherapeutic ap-
proaches have mainly concentrated on leukocyte FcR for IgG (FcR;
Ref. 9). Three classes of FcR are currently recognized: FcRI
(CD64), FcRII (CD32), and FcRIII (CD16; Refs. 10, 11). FcRI
represents the only receptor class capable of binding monomeric IgG.
It has a limited cell distribution and exhibits potent immune-activating
activities. Because of these characteristics, this receptor has been
considered an optimal trigger molecule for Ab therapy (12). Although
granulocytes are not often considered primary mediators of ADCC,
they are among the most common leukocytes, can be induced to
express FcRI (13), and can mediate ADCC via FcRI (14).
Whereas the acceptance of cancer immunotherapy as part of stand-
ard clinical practice is relatively new, immunotherapy of cancer is an
old concept. At the end of the 19th century, Coley (15, 16) observed
therapeutic effects in cancer patients treated with a crude bacterial
extract. At that time, the role of the immune system in combating
disease was poorly understood, and Coley’s results were neither
reproducible nor understood from a mechanistic point of view. The
past 20 years have seen striking advances in the field of immunology.
Some of these advances reflect back on Coley’s observations. In
particular, we now know that specific sequences within bacterial DNA
contain unmethylated CpG dinucleotides that are potent immuno-
stimulatory motifs (17, 18). Synthetic ODNs containing such un-
methylated CpG motifs mediate similar effects (19). In particular,
CpG ODNs are able to activate immune effector cells and enhance
cytotoxicity against tumor targets (20). In animal models, CpG ODNs
have potent antitumor effects when administered in vivo either alone
or in combination with mAb (21–23). Interestingly, the effect of CpG
ODNs on various effector cells varies depending on the sequence of
the CpG ODNs (20, 24). CpG ODNs with a chimeric backbone in
combination with poly-G tails are known as CpG A (also known as
“D” type ODNs; Ref. 24). These CpG ODNs are potent inducers of
IFN- production and NK lytic activity, but have little effect on
secretion of Th1-type cytokines or B-cell proliferation. In contrast,
CpG B (also known as “K” type ODNs) are potent activators of B
cells and induce production of Th1-type cytokines. CpG A can induce
regression of established NK-sensitive melanomas in mice (22)
whereas CpG B does not. In contrast, CpG B is effective at inducing
regression of the EL4 murine lymphoma where both NK cells and T
cells contribute to the antitumor effect. CpG A is not as active in this
model.
Use of the combination of Abs and immunostimulatory agents, such
as CpG ODNs, should allow us to combine the specificity of Abs with
the potency of the innate immune system. However, doing so in a
rational fashion requires an understanding of the potential interaction
between these different but interactive arms of the immune system. In
the murine studies outlined below, we explore the cellular effectors
responsible for the antitumor effects of mAbs when administered
either alone or in combination with immunostimulatory CpG ODNs of
the A or B class. The results of these studies demonstrate that different
types of effector cells can contribute to ADCC, and point to the
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potentially potent activity of granulocytes and other FcRI-expressing
cells in the antitumor effect of mAbs alone and Abs plus CpG B in
vivo. Perhaps most importantly, they highlight the concept that a
growing understanding of the cellular mechanisms responsible for the
antitumor effects of mAbs should allow us to develop rationally
designed combination immunotherapeutic approaches.
MATERIALS AND METHODS
Tumor Cell Lines. The T3C variant of the 38C13 mouse lymphoma cell
line (Ref. 25; henceforth referred to as 38C13) were cultured in medium
consisting of RPMI 1640 (Life Technologies, Inc., Rockville, MD) supple-
mented with 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT),
50 g/ml streptomycin, 50 IU/ml penicillin, and 4 mM L-glutamine (complete
medium) supplemented with 2-mercaptoethanol. SK-BR-3, a human breast
carcinoma cell line overexpressing HER-2/neu, was obtained from the Amer-
ican Type Culture Collection (Manassas, VA; HTB-30; Ref. 26). The 3-meth-
ylcholantrene-induced mouse fibrosarcoma cell line, CMS7HE, stably trans-
fected with human HER-2/neu, together with a control cell line, transfected
with an empty vector, CMS7neo, were kindly provided by Dr. Hiroshi Shiku
(Mie University School of Medicine, Mie, Japan; Refs. 27, 28). These cells
were maintained in complete medium, and in case of the CMS7 cell lines
supplemented with 462 g/ml Geneticin (G418 sulfate; Life Technologies,
Inc.). All of the adherent cell lines were detached by using trypsin-EDTA (Life
Technologies, Inc.) in PBS. Cells used for tumor inoculation were collected in
log-phase, and were tested for stable HER-2/neu expression by FACS analy-
ses, and for potential Mycoplasma contamination before each experiment.
CpG ODN. CpG ODN 1585 (sequence GGGGTCAACGTTGAGGG-
GGG; Ref. 22) and CpG ODN 1826 (TCCATGACGTTCCTGACGTT; Ref.
29) were used as prototypic CpG A and CpG B, respectively, as we have done
previously (22). ODN 1982 (TCCAGGACTTCTCTCAGGTT) was used as a
control sequence. All of the ODNs were supplied by Coley Pharmaceutical
Group (Wellesley, MA). CpG ODNs were tested and proved to contain 12.5
ng/mg of lipopolysaccharides levels by Limulus assays (LAL-assay; BioWhit-
taker, Walkersville, MD). ODNs were injected i.p. at a dose of 100 g in 0.2
ml PBS unless otherwise stated.
Flow Cytometry. Whole mouse blood, WBCs, or tumor cells were incu-
bated for 30 min with either labeled or unlabeled mAb. Labeled cells were
washed three times in PBS supplemented with 1% bovine serum albumen and
0.01% azide. When unlabeled primary mAbs were used, indirect staining,
using FITC- or r-phycoerythrin-labeled F(ab)2 fragments of a goat -mouse
mAb as a labeled second Ab was performed. Whole blood samples were lysed
and fixed by using FACS lysing solution (Becton Dickinson, San Jose, CA).
All of the samples were analyzed on a FACSCalibur flow cytometer (Becton
Dickinson). A panel of antimouse mAb, labeled with either FITC or r-
phycoerythrin, was used to detect the different mouse effector cell populations.
Unconjugated murine mAbs against HER-2/neu (520C9; mouse IgG1) were
provided by Medarex (Medarex Inc., Annandale, NJ).
ADCC Assay. A 51Cr release assay, slightly modified from Valerius et al.
(13) was used. Mouse whole blood was used as the source of effector cells.
Mice were treated for 3 days with 150 g of mG-CSF s.c., kindly provide by
Dr. Jeff Andresen (Amgen, Thousand Oaks, CA), to increase circulating
numbers of leukocytes before blood collection via orbital puncture. Briefly,
tumor cells were incubated with 200 Ci 51Cr for 2 h. After washing three
times with culture medium, 5 103 target cells were added to round-bottomed
microtiter plates containing 50 l of whole blood, CpG ODNs, and sensitizing
mAbs. The final volume was 200 l, and the E:T cell ratio was 80:1. After
incubation overnight at 37°C, assays were stopped by centrifugation. 51Cr-
release was measured in supernatants from triplicate wells. Percentage of
cellular cytotoxity was calculated using the formula:
% specific lysis 
experimental cpm  basal cpm
maximal cpm  basal cpm
 100
with maximal 51Cr release determined by adding Zap-oglobin (Coulter Elec-
tronics LTD, Luton, England; 10% final concentration) to target cells, and
basal release measured in the absence of sensitizing mAb and effector cells.
Only very low levels of Ab-mediated noncellular cytotoxicity (without effector
cells) and Ab-independent killing were observed under these conditions (5%
specific lysis).
38C13 Murine Lymphoma Model. The 38C13 murine lymphoma tumor
model has been described previously (30–32). Female C3H or C6B3F1
(C3H  C57Bl6 F1) mice were purchased from Harlan Biosciences, (Indian-
apolis, IN), housed in the University of Iowa Animal Care Facility, and used
when they were 6–9 weeks old. For in vivo experiments, 5 103 cells growing
in log phase were injected i.p. into immunocompetent mice. Day 0 was defined
as the day of tumor inoculation. The therapeutic murine mAb MS11G6
(IgG2a) and MS5A10 (IgG1; Ref. 25) were obtained from tissue culture
supernatant by protein A (MS11G6) or protein G (MS5A10) affinity chroma-
tography. Mice were treated with doses of 0.1 mg therapeutic mAb in 0.2 ml
PBS i.p. as indicated. The University of Iowa or University of Utrecht animal
care and use committees approved all of the mice experiments.
NK and Granulocyte Depletion. NK cells were depleted in vivo by i.p.
injection of 0.1 mg of the anti-NK1.1 mAb PK136 (ATCC HB191) on days
2, 0, 3, 5, 7, and 10. C6B3F1 mice were used for deletion studies, because
NK cells from C3H/HeN mice do not express the NK1.1 antigen. Preliminary
studies demonstrated that NK cells from C6B3F1 express NK1.1 and are
depleted after PK136 therapy as determined by flow cytometry and functional
assays for NK activity (lysis of YAC-1 cells). In addition, the in vivo devel-
opment of lymphoma and survival after inoculation with 38C13 cells in
C6B3F1 mice is indistinguishable from that in homozygous mice C3H/HeN
mice, and the antilymphoma effect of MS11G6 is similar in homozygous
C3H/HeN and C6B3F1 mice (data not shown). Granulocytes were depleted by
i.p. injection of 0.1 mg of mAb RB6-8C5 (Anti Ly-6G; Kindly supplied by Dr.
J. Harty, University of Iowa) on days 2, 3, 5, and 10. Depletion of granu-
locytes from the peripheral blood for up to 10 days after tumor inoculation was
confirmed by examination of peripheral blood smears.
Human FcRI Tg Mice. FVB/N mice Tg for hFcRI (CD64) were
crossed back into BALB/c (33, 34). In all of the experiments with hFcRI
animals, the Tg mice were matched with their NTg littermates. Mice were bred
and maintained in the Tg Mouse Facility of the Central Laboratory Animal
Facility (Utrecht, the Netherlands) and were used at 8–16 weeks of age.
Solid Tumor Model. Tumor cells were tested for stable HER-2/neu ex-
pression after in vivo passage by FACS analyses. CMS7HE cells (2  106)
were injected s.c. in the right flank of male F12 Tg-hFcRI and NTg mice (27).
These tumors grew quickly and could easily be measured using calipers.
Tumor diameter was reported as length  width  height (mm3). BsAb
MDX-H210 (hFcRIa  HER-2/neu), produced by chemically cross-linking
F(ab) fragments of the target Abs H22 (hFcRI), and 520C9 (HER-2/neu) was
supplied by Medarex (35). MDX-H210 was injected i.p. and CpG ODN s.c. in
the vicinity of the tumor as indicated. Mice were checked three times a week
for signs of toxicity and discomfort, including level of activity, ruffled fur,
diarrhea, and general appearance.
Statistical Analysis. Group data were reported as mean  SE. Differ-
ences between groups were analyzed by unpaired (or, when appropriate,
paired) Student’s t tests. Levels of significance are indicated, with signif-
icance accepted at the P  0.05 level. Statistical analyses on survival
curves were performed using Prism 3.02 software (GraphPad Software,
Inc., San Diego, CA).
RESULTS
Both CpG A and CpG B Enhance the Efficacy of mAb Therapy.
As outlined above, we have found monotherapy with CpG A (1585)
to be more effective than CpG B (1826) in the treatment of NK-
sensitive malignancy, whereas CpG B is more effective in models
where T cells were found to be responsible for much of the antitumor
activity (22). We also demonstrated previously that the efficacy of
antitumor IgG2a is significantly enhanced by cotherapy with CpG B
(29, 36). If NK cells play the central role in the enhanced ADCC
induced by CpG ODNs, we would expect CpG A to be more effective
than CpG B at enhancing the efficacy of mAb therapy, whereas CpG
B would be more effective if most of the antitumor activity is
mediated by other effector cells. Both CpG A and CpG B enhanced
the efficacy of IgG2a mAb therapy to a similar degree under a broad
5596
CpG A AND B, ANTIBODY EFFICACY, AND EFFECTOR MECHANISMS
range of conditions including studies where therapy was given once
early in tumor development (data not shown) and studies of delayed
therapy using multiple doses of mAb and CpG ODN (Fig. 1). This
suggests that both CpG A and CpG B can activate effector cell
populations capable of mediating ADCC.
Antitumor Activity of IgG1 and IgG2a mAb in Combination
with CpG ODN. When used as a single agent, neither CpG A nor
CpG B had a detectable antitumor effect in the 38C13 lymphoma
model in vitro or in vivo. However, this does not exclude the possi-
bility that the synergy between mAb and CpG ODN is because of
direct effects on the malignant cells of the combination of mAb and
CpG ODN. We previously produced and evaluated a panel of synge-
neic, anti-38C13 mAbs with identical specificity but varied isotypes
(25). mAbs of the murine IgG2a isotype have Fc that react with both
FcRIII (CD16) and FcRI (CD64), whereas mAb of the murine IgG1
isotype have lower affinity for FcRI (37), particularly when the mAb
is in its monomeric form. Thus, one would expect the antitumor IgG2a
mAb to be capable of mediating ADCC via a variety of effector cell
types, whereas the antitumor IgG1 of the same specificity would
signal as well, but would not mediate ADCC as well. Therefore, we
evaluated therapy of tumor-bearing mice with antitumor IgG1 com-
bined with CpG A or CpG B. Neither CpG A nor CpG B had a
detectable effect on the efficacy of antitumor IgG1 mAb using con-
ditions where both CpG A and CpG B enhance the efficacy of IgG2a
mAb (Table 1). In addition, antitumor F(ab)2 had no detectable
antitumor activity either alone or combined with CpG ODN. These
studies indicate that the enhanced antitumor effect of mAb plus CpG
ODN requires interaction with an effector cell population that has
receptors for IgG2a, and supplies additional evidence that enhanced
ADCC, and not signaling on the tumor cell, is responsible for the
observed antitumor effects in this model.
NK Cells Are Responsible for the Efficacy of CpG A Plus mAb,
Whereas a Variety of Effector Cells Contribute to the Efficacy of
CpG B Plus mAb. Additional studies were done to explore the role
of NK cells in the antitumor effect of IgG2a mAb when used alone or
in combination with either CpG A or CpG B. Depletion of NK cells
markedly decreased the efficacy of mAb plus CpG A. In contrast,
depletion of NK cells with anti-NK1.1 alone had little effect on the
antitumor activity of mAb alone (Table 1) or mAb plus CpG B (Fig.
2B). This finding is consistent with prior studies that suggest the major
effector cell activated by CpG A is the NK cell. In contrast, CpG B
activates a variety of cell populations that could mediate enhanced
ADCC in the absence of NK cells.
Depletion of Both Granulocytes and NK Cells Decreases the
Therapeutic mAb Efficacy of CpG B Plus mAb. Activated granu-
locytes can express FcRI and can mediate ADCC (38). Therefore,
we evaluated the importance of granulocytes, both alone and in
combination with NK cells, in mediating the antitumor activity of
mAb and CpG B in the 38C13 lymphoma model. Depletion of
granulocytes alone had little impact on efficacy of mAb alone (Table
1) and mAb plus CpG B (Fig. 3). However, depletion of both NK cells
and granulocytes decreased the efficacy of therapy under both of these
conditions. Additional studies were done to confirm that this de-
creased survival in NK and granulocyte-depleted mice was because of
changes in antilymphoma activity of mAb, and not to other immuno-
logical changes induced by effector cell depletion. Postmortem ex-
amination of select mice demonstrated that mice died of widespread
lymphoma and not infection. Depletion of NK cells and granulocytes
had no detectable impact on the behavior or survival of tumor-free
mice or on the growth of tumor in mice that were not treated with
mAb (data not shown). We also explored the pharmacokinetics of
antilymphoma mAb to confirm that the procedures used to deplete NK
cells or granulocytes did not impact on clearance of the therapeutic
mAb. Depletion had no effect on the levels of the antilymphoma mAb
(data not shown).
Fig. 1. Both CpG A and CpG B can enhance the efficacy of therapy with antilymphoma
IgG2a mAb. Mice were inoculated i.p. with 38C13 tumor cells on day 0, and treated with
CpG ODN and mAb on days 5, 7, and 10 with 100 g anti-lymphoma IgG2a mAb
(MS11G6) alone or with 20 g of CpG ODN 1585 (CpG A) or CpG ODN 1826 (CpG B).
Survival was recorded daily. Similar results were found in three independent experiments.
Fig. 2. Depletion of NK cells decreases the efficacy of mAb plus CpG A, but has no
effect on the efficacy of mAb plus CpG B. Mice were inoculated i.p. with 38C13 T3C
tumor cells on day 0. They were treated with a single dose of 100 g MS11G6 and 100
g CpG ODN on day 3. NK cells were depleted by i.p injection of Anti NK1.1 mAb
(PK136) on days 3, 0, 3, 6, 10, and 13. A, mice treated with mAb plus CpG A. B, mice
treated with mAb plus CpG B. Similar results were found in three independent experi-
ments.
Table 1 Summary of in vitro and in vivo effects of CpG A and CpG B
No ODN CpG A CpG B
Enhances therapeutic effect of antitumor IgG2a  Yes Yes
Enhances therapeutic effect of antitumor IgG1 or F(ab)2  No No
NK depletion decreases efficacy with mAb therapy / ODN No Yes No
Granulocyte depletion decreases efficacy with mAb therapy / ODN No No No
NK and granulocyte depletion decreases efficacy with mAb therapy / ODN Yes Yes Yes
Induces upregulation of hFcRI  No Yes
Enhances anti-tumor effect of anti-hFcRI  anti-HER-2/neu BsAb  Not tested Yes
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Human FcRI is Up-Regulated by CpG B. The data outlined above
suggest effector cells that express FcRI mediate the enhanced antitumor
activity observed when CpG B is added to mAb. Furthermore, granulo-
cytes can play an important role in the antitumor effects observed with
this therapy. Therefore, we evaluated the effect of CpG ODN on FcRI
expression. Because Abs against murine FcRI were not yet available,
we used an hFcRI Tg mouse model to assess FcRI expression and
function. This model has been described previously (33). Tg hFcRI
mice express hFcRI under control of the endogenous human FcRI
promotor. Human FcRI Tg mice constitutively express hFcRI on
monocytes, macrophages, immature DCs, and in low numbers on resting
granulocytes (34) as would expected for FcRI. In addition, expression of
hFcRI on granulocytes in this model is up-regulated in vivo upon
stimulation with IFN- or granulocyte colony-stimulating factor (34, 39,
40). Human FcRI expression was determined at various time points
after a single s.c. dose of CpG ODN. As illustrated in Fig. 4, enhanced
hFcRI expression by granulocytes was seen in Tg mice treated in vivo
with CpG B. In contrast, little if any change in hFcRI expression was
seen with CpG A, even at a high dose. No hFcRI was detected in NTg
mice. A clear time-response curve is seen with hFcRI expression after
a single s.c. dose of CpG B, with hFcRI expression up-regulated for	8
days after a single 100g dose of CpG B. Treatment with CpG B, but not
CpG A, enhanced hFcRI expression levels on monocytes and DCs as
well in a dose-dependent manner (data not shown).
Tumor Cell Killing in Vitro Mediated by hFcRI Is Enhanced
by CpG B. Next, we investigated whether CpG B had an impact on
ADCC. This was done using the hFcRI-directed BsAb MDX-H210.
Effector cells for these assays were harvested by obtaining whole
blood from mG-CSF-treated mice and incubating the blood in vitro
with CpG B. Tg granulocytes activated with CpG B exhibited en-
hanced MDX-H210, mediated cell killing, with the combination of
MDX-H210 and CpG B being effective at very low MDX-H210
concentrations (Fig. 5). No specific lysis was observed with a control
CpG B. Non-Tg granulocytes were unable to mediate lysis, except via
mAb 520C9, an anti-HER-2/neu mouse IgG1 mAb that initiates
cytotoxicity via mFcRII/III (41).
Therapy with hFcRI  HER/2-neu BsAb and CpG B Inhibits
Tumor Growth. Additional studies were done to evaluate the in vivo
effect of CpG B and BsAb using hFcRI Tg mice, MDX-H210, and
mouse fibrosarcoma cells that express the HER-2/neu target antigen
(CMS7HE). In vitro studies indicated that CpG B had no detectable
effect on tumor cell morphology, proliferation, antigen expression, or
viability (data not shown). Clear reduction in tumor growth was
observed in Tg mice treated with the combination of MDX-H210 and
CpG B, whereas tumors grew progressively in all of the other treat-
ment groups (Fig. 6), and in control ODN (1982)-treated and NTg
mice (data not shown). Treatment in Tg mice with the MDX-H210
alone did not induce an antitumor effect. This is most probably
because of inadequate expression of FcRI by nonstimulated effector
cells, thereby limiting FcRI-mediated targeting and cytotoxicity.
Paradoxically, tumors in animals treated with BsAb alone appeared to
grow faster than tumors in control mice; however, this difference was
not statistically significant.
DISCUSSION
mAbs are now an accepted component of lymphoma and breast
cancer therapy. Nevertheless, there is still much that we do not
understand about their mechanism of action. Most investigators agree
that ADCC plays a major role in the observed responses. Two pop-
ulations of effector cells (NK cells and monocytes/macrophages) have
received the most attention as mediators of ADCC.
Given that CpG ODNs activate NK cells, monocytes, and macro-
phages, and induce production of immunostimulatory cytokines, it is
rational to explore how CpG ODN impacts on the efficacy of mAb
therapy, and which effector cells contribute to this antitumor activity.
We used the differential effects of CpG A and CpG B to assess which
effector cells contribute to the antitumor effect of therapy with mAb
plus CpG ODN. CpG A (1585) and CpG B (1826) enhanced the
efficacy of mAb to a similar degree. However, this enhanced effect
was mediated by different effector cell populations. For CpG A, NK
Fig. 4. In vivo therapy with CpG B but not CpG A induces up-regulation of hFcRI by
granulocytes. Human FcRI-Tg mice and NTg littermates serving as controls were
injected s.c. with 100 l vehicle (PBS) or a single dose of 10 or 100 g CpG ODN A or
CpG ODN B. Human FcRI expression on granulocytes was determined by FACS
analysis between 0 and 8 days after CpG ODN therapy. All determinations were per-
formed in triplicate. Results represent mean from two independent experiments;
bars, SD.
Fig. 5. CpG ODN B enhances ADCC mediated by anti-hFcRI x anti-HER-2/neu
BsAb. Tg and NTg mice were treated with mG-CSF for 3 days to increase granulocytes
numbers. Whole blood was harvested from mice and incubated with various concentra-
tions of monospecific anti-HER-2/neu mAb (520C9) or BsAb (MDX-H210), along with
10 g/ml of CpG B or control ODN. Effector cells were mixed with 51Cr-labeled SK-Br-3
cells as outlined in “Materials and Methods,” and percentage specific lysis determined. All
determinations were performed in triplicate in each experiment. Results from three
independent experiments; bars, SD.
Fig. 3. Depletion of both granulocytes and NK cells decreases the efficacy of therapy
with mAb plus CpG B. In vivo studies were done to assess whether depletion of
granulocytes impacts on the efficacy of mAb therapy plus CpG B. NK cells and
granulocytes were depleted using anti-NK1.1 mAb (PK136) or anti Ly-6G mAb (RB6-
8C5), respectively, as outlined in “Materials and Methods.” Treatment was given as
outlined in Fig. 2. Survival was recorded daily. Similar results were found in three
independent experiments.
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cells played the central role, with the enhanced antitumor effect being
lost after depletion of NK cells. In contrast, the antitumor effect of
mAb plus CpG B could be mediated by either granulocytes or NK
cells, because depletion of either population alone had little impact on
efficacy, whereas depletion of both types of effector cells resulted in
a loss of the therapeutic effect.
Use of Ab to deplete various cell populations has its limitations.
Although we administered anti-NK and antigranulocyte mAb frequently
with the goal of complete depletion, and were unable to find NK cells or
granulocytes after depletion during the critical therapeutic window of the
antitumor mAb, depletion may not have been complete. Residual NK
cells or granulocytes may have contributed to the residual antitumor
activity either by mediating ADCC or supplying cytokines that contrib-
uted to activating other cellular effectors. It is also possible that this
approach resulted in unintentional depletion of a cell population that was
important for the antitumor activity of therapy. This is particularly im-
portant in interpretation of the granulocyte depletion studies, which were
done using the anti-LY-6C mAb Gr-1. Whereas this mAb clearly can
deplete granulocytes, it has also been reported that the LY-6C target
antigen is expressed by other cell populations, including plasmacytoid
DC (42). The ability of this population of DC to produce IFN- is
enhanced by CpG ODN (43, 44). Thus, an alternative explanation for the
observed findings is that depletion with Gr-1 decreased the efficacy of
therapy by eliminating the IFN--producing cell. If this was the case, we
would have expected depletion with Gr-1 to significantly decrease the
therapeutic efficacy of mAb and CpG A, because the primary mechanism
of action proposed for CpG A is induction of IFN- production by
plasmacytic DC, with secondary activation of NK cells. In fact, Gr-1
depletion had no detectable effect on therapy with mAb plus CpG A
(Table 1), suggesting that our proposed mechanism, namely granulocyte
depletion, and not depletion of IFN--producing cells, was responsible
for the observed effects.
A second approach to exploring the role of various effector cells is to
evaluate antitumor effects using BsAb that engage effector cells in a more
focused manner. Granulocytes can express FcR and so could also con-
tribute to the observed antitumor effects of mAb. In vivo studies in mice
and data from clinical trials of the hFcRI-directed BsAb, MDX-H210,
have shown that granulocytes can be retargeted and demonstrate biolog-
ical activity (8, 12, 45–49). To assess whether CpG ODNs enhance the
efficacy of ADCC at least in part by inducing up-regulation of hFcRI on
granulocytes, we evaluated the effect of CpG B on hFcRI expression
and function. hFcRI expression on murine granulocytes was up-regu-
lated by a single low dose of CpG B in vivo. In addition, whole blood
obtained from mG-CSF-treated hFcRI Tg mice and stimulated in vitro
with CpG B enhanced the ability of that blood to mediate ADCC.
Up-regulation of hFcRI on monocytes, macrophages, and DCs, and
ADCC mediated by these cells, could have been responsible for some of
the enhanced hFcRI-mediated ADCC seen with CpG B. However,
mG-CSF stimulated blood has low numbers of these cells. The E:T ratio
would have been inadequate to mediate ADCC if the granulocytes were
not contributing to the cytotoxic effect.
TLR9 is a key receptor in the response to CpG ODNs (50). A
coreceptor responsible for the differential effects of CpG A and CpG B
has been hypothesized but has not yet been identified. Production of a
variety of cytokines by subsets of DCs (44) appears to be particularly
important in the systemic response to CpG ODNs in both the murine and
human systems. Interestingly, purified murine monocytes express TLR9,
whereas purified human monocytes do not. This and other species dif-
ferences related to response to CpG ODNs need to be taken into account
when applying results in murine models to humans. Nevertheless, there
are key similarities in the response of mice and humans to CpG ODNs.
For example, in a recently completed Phase I clinical study, CpG ODN
was found to enhance production of tumor necrosis factor , interleukin
12, IFN-, and IFN-. Some of the cytokines produced in response to
CpG ODN in the human system, such as IFN-, up-regulate FcRI and
activate monocytes indirectly. Indirect mechanisms are also responsible
for the effects that CpG ODN has on granulocytes, because TLR9 is not
expressed by murine or human granulocytes. CpG A and CpG B have
similar, although not identical, effects on immune cell populations and
cytokine production in mice and humans. Thus, there is reason to hy-
pothesize that the differences in response to CpG A and CpG B observed
in the murine models described here could be found in humans as well.
In conclusion, the studies outlined above supply valuable information
related to the cellular effector mechanisms responsible for the antitumor
effects seen with mAb alone, and when combined with CpG A or CpG
B. CpG A enhances the efficacy of mAb therapy largely by activating NK
cells, whereas CpG B activates multiple effector cell populations. Both
classes of ODN are effective only when used with mAbs that are potent
mediators of ADCC. Granulocytes appear to play an important role, and
may be responsible for much of the synergistic effect seen with the
combination of mAb and CpG B. Human FcRI expression on granulo-
cytes is up-regulated by CpG B. This FcR is likely responsible for much
of the enhanced lysis seen with BsAb and CpG B. A number of important
questions remain. We do not know the contribution of monocytes and
macrophages, because hFcRI is also up-regulated on these cells by CpG
B. It remains unclear whether the contribution of NK cells and granulo-
cytes is because of their ability to mediate ADCC directly, or whether
their role is more indirect because of production of cytokines that con-
tribute to activation of other cell populations. Whereas animal models are
useful, they do not always reflect the mechanisms responsible for the
efficacy of mAbs used for human disease. Clinical trials of mAb plus
CpG B, with clinical correlative studies, have begun recently, and will
supply important information related to whether the promising results in
animal models can be duplicated in the clinic. Ongoing preclinical and
clinical evaluation of mAb mechanisms of action, including assessment
of the role of monocytes and macrophages, and immunotherapeutic
approaches in involving mAb plus other immunologically active agents is
also needed if we are to determine which cellular effectors are responsible
for the antitumor effects of mAb and use this information to develop the
next generation of rationally designed immunotherapeutic approaches.
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